Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocertatug rezetecan vs Chemotherapy in Endometrial Cancer
NCT07286331Phase 3Recruiting
- Sponsor
- GSK
- Start
- Jun 2026
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of mocertatug rezetecan in endometrial cancer (EC), sponsored by GSK. Started Jun 2026; status: recruiting.
02
Drugs
mocertatug rezetecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07286331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07286331.